

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/230831465>

Design, Synthesis, and Structure–Activity Relationship of N–Arylnaphthylamine Derivatives as Amyloid Aggregation Inhibitors

ARTICLE in JOURNAL OF MEDICINAL CHEMISTRY · SEPTEMBER 2012

Impact Factor: 5.45 · DOI: 10.1021/jm301105m · Source: PubMed

CITATIONS

11

READS

31

15 AUTHORS, INCLUDING:



Roberto Di Santo

Sapienza University of Rome

129 PUBLICATIONS 1,756 CITATIONS

SEE PROFILE



Roberta Costi

Sapienza University of Rome

101 PUBLICATIONS 1,452 CITATIONS

SEE PROFILE



Giuliana Cuzzucoli Crucitti

Sapienza University of Rome

16 PUBLICATIONS 87 CITATIONS

SEE PROFILE



Silvio Caccia

217 PUBLICATIONS 4,992 CITATIONS

SEE PROFILE

Design, Synthesis, and Structure–Activity Relationship of N-Arylnaphthylamine Derivatives as Amyloid Aggregation Inhibitors

Roberto Di Santo,^{*,†} Roberta Costi,[†] Giuliana Cuzzucoli Crucitti,[†] Luca Pescatori,[†] Federica Rosi,[†] Luigi Scipione,[†] Diana Celona,[‡] Mario Vertechy,[‡] Orlando Ghirardi,[‡] Paola Piovesan,[‡] Mauro Marzi,[‡] Silvio Caccia,[§] Giovanna Guiso,[§] Fabrizio Giorgi,[‡] and Patrizia Minetti^{*,‡}


[†]Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur—Fondazione Cenci Bolognetti, “Sapienza” Università di Roma, P.le A. Moro 5, I-00185 Roma, Italy

[‡]Sigma-Tau S.p.A., Via Pontina, Km 30.400, I-00040 Pomezia, Italy

[§]Dipartimento di Neuroscienze, Istituto di Ricerche Farmacologiche “Mario Negri”, Via La Masa, 19, I-20156 Milano, Italy

S Supporting Information

ABSTRACT: Dyes like CR are able to inhibit the aggregation of A β fibrils. Thus, a screening of a series of dyes including ABBB (1) was performed. Its main component **2** tested in an in vitro assay (i.e., ThT assay) showed good potency at inhibiting fibrils association. Congeners **4–9** have been designed and synthesized as inhibitors of A β aggregation. A number of these newly synthesized compounds have been found to be active in the ThT assay with IC₅₀ of 1–57.4 μ M. The most potent compound of this series, **4k**, showed micromolar activity in this test. Another potent derivative **4q** (IC₅₀ = 5.6 μ M) rapidly crossed the blood–brain barrier, achieving whole brain concentrations higher than in plasma. So **4q** could be developed to find novel potent antiaggregating β A agents useful in Alzheimer disease as well as other neurological diseases characterized by deposits of amyloid aggregates.



■ INTRODUCTION

Alzheimer's disease (AD) is a degenerative brain disorder and a major cause of dementia for which no cure is known. Currently, more than 35 million people worldwide are believed to suffer from this disease, and with the aging of the population this number is expected to increase by a factor of 3–4 over the next 40 years.¹

The presence of extracellular β -amyloid (A β) peptide fibrils deposits and the presence of intracellular neurofibrillary tangles (NFT) made by abnormally hyperphosphorylated protein tau are among the clearest signs of AD. These two events, which involve mainly the medial temporal lobe structures, in particular the hippocampus and cortical areas of the brain, are necessary conditions for the onset of the disease, even if the final pathological picture of the disease involves the whole central nervous system.^{2,3} These microscopic aggregates are still well beyond the resolution of conventional neuroimaging techniques (positron emission tomography, computerized tomography, magnetic resonance imaging) used for the evaluation of patients with AD. Selective tau imaging for in vivo NFT quantification is still in the early stages of development.⁴ Since A β is at the center of AD pathogenesis and given that several pharmacological agents aimed at reducing A β levels in the brain are being developed and tested, many efforts have focused on generating radiotracers or agents that allow A β imaging in vivo.^{5–7}

The main constituents of A β fibrils, A $\beta_{(1-40)}$ and A $\beta_{(1-42)}$, normally present as soluble species in extracellular fluids, twisted around each other, resulting in filamentous structures with a diameter of 6–10 nm. Amyloid fibrils have been defined as thermodynamically stable, structurally organized, and highly insoluble, having affinity for the Congo Red (CR) stain⁸ and filamentous protein aggregates being composed of repeating units of β -sheets aligned perpendicular to the fiber axis, with potentially parallel and antiparallel organization.⁹ In AD, the amyloid fibers accumulate outside the cell in the extracellular spaces of the brain and in the tunica media of the cortical and meningeal arterioles, producing three different macroscopic changes: senile plaques and diffuse plaques which can be differentiated by the presence or absence of modifications in the neuronal processes around the central amyloid deposit, and amyloid angiopathy, which represents an infiltration of amyloid fibers between the smooth muscle fibers and the internal elastic lamina of the arterial wall.¹⁰ The clinical manifestations of this progressive and irreversible dementia, in which are implicated the A $\beta_{(1-42)}$ aggregated fibrils, are the progressive loss of memory and cognitive functions.¹¹ In general, the damage caused by A β aggregation may be summarized by the following: (i) changes in amyloidogenesis; (ii) increase in the vulnerability

Received: July 27, 2012

Published: September 11, 2012




Figure 1. **1**, **2** (main component of a commercial mixture of **1**), and **3** (pamoic acid).

of neurons to excitotoxicity; (iii) increase in the vulnerability of the neurons to hypoglycaemic damage; (iv) changes in the homeostasis of calcium; (v) increase in damage by oxidation; (vi) activation of inflammatory mechanisms; (vii) activation of the microglia; (viii) induction of lysosomal proteases; (ix) changes in the phosphorylation of the protein tau; (x) induction of apoptosis; (xi) damage to membranes.¹²

Since the toxicity and neurodegeneration in AD are attributed to soluble intermediate oligomers and to a lesser extent to amyloid fibrils,¹³ agents that prevent or reverse the oligomerization and/or fibrillization of A β may have potential therapeutic application in the treatment of AD.¹⁴ From a purely theoretical point of view, the reduction of the damage caused by A β can be addressed through different therapeutic approaches: (i) reducing the production of A β using inhibitors of the secretases to change the metabolism of the APP (increasing the α or reducing the β and γ secretases); (ii) preventing or blocking the aggregation of the A β ; (iii) increasing the clearance of the A β ; (iv) blocking the neurotoxic effects of A β restoring calcium homeostasis; (v) preventing the toxicity due to the free radicals; (vi) preventing excitotoxicity; (vii) reducing the damage caused by the inflammatory response; (viii) correcting the imbalance between zinc and copper; (ix) inhibiting neuronal apoptosis.^{15–17} Efforts at searching for inhibitors of A β aggregation have demonstrated that small molecules, containing single or multiple (hetero)-aromatic rings often bearing hydroxyl group, can inhibit protein–protein interaction.¹⁸ Several molecular dynamics studies suggest that the driving forces governing the A β assembly might include aromatic packing, hydrophobic forces, and electrostatic interactions.^{19–21} The hydrophobic interaction between A β side chain leading to A β fibrillization could be blocked by small molecules competing with such an association, ultimately leading to inhibition of fibril formation.²² These interactions could be reinforced by hydrogen bond formation between hydroxyl or methoxy groups on aromatic rings of the inhibitor and hydrogen bond acceptor groups of A β .

To date, no specific therapy exists to prevent, slow down, or arrest the amyloidogenic processes at the root of AD. Indeed the treatments currently used for this disease are exclusively symptomatic, and even if they act on various aspects, they fundamentally only interfere with the neurotransmitter mechanisms, which govern learning and memory. The substances mostly used include the reversible inhibitors of acetylcholinesterase, such as tacrine, donepezil, and rivastigmine.²³

Our initial attempts at generating small molecule inhibitors of A β aggregation were based on the knowledge that CR showed some affinity for amyloid protein fibrils. Thus, we decided to screen a few dyes as potential inhibitors of the A β aggregation, and among them we found that alizarin blue-black B (ABBB) (**1**) (Figure 1) (Sigma-Aldrich mordant black [1324-21-6]) showed interesting potency in inhibiting the fibrils association in the ThT assay.^{24,25}

However, **1** as sold by Aldrich was well-known to be a mixture of anthraquinone derivatives that necessitated purification for elucidation of the nature of the various components. Within the commercial mixture of **1** we isolated and identified the major component (~40%) as the 3,4-dihydroxy-1-[1-(4-sulfophenylamino)]anthracene-9,10-dione (**2**) and tested it for its ability to inhibit the A β aggregation in the ThT assay. Compound **2** was an efficient inhibitor showing $IC_{50} = 1.1 \mu M$. In parallel, during research performed at our company on negatively charged compounds as inhibitors of A β aggregation, we discovered that pamoic acid (**3**) (Figure 1) demonstrated some inhibiting properties with regard to A β aggregation in *in vitro* assays, showing $IC_{50} = 38.2 \mu M$.

The above data stimulated us to design new compounds structurally related to **2** and **3** as A β aggregation inhibitors. In particular, *N*-arylnaphthylamine derivatives **4**, in which the anthraquinone moiety of **2** was replaced by naphthalene ring typical of compound **3**, were designed (Figure 2). This replacement




Figure 2. *N*-Arylnaphthylamines (**4–7**) and thio analogues **8** and **9** designed as A β aggregation inhibitors (for substituents R and R₁, see Table 1).

was motivated by the fact that 9,10-anthraquinone derivatives, such as antitumor agent adriamycin, are known to generate *in vivo* toxic metabolites that are particularly noxious for heart tissues.²⁶

Some analogues of **4** such as compounds **5–8** were further designed to better define the structure–activity relationship (SAR) within this class of inhibitors (Figure 2). As a first step in these preliminary SAR studies, N and S linkers between the two aromatic rings were chosen essentially because of easier synthetic feasibility.

The rationale to design *N*-arylnaphthylamines as inhibitors of A β aggregation has also been strengthened by reports on *N*-phenylantranilic derivatives, represented by compounds **10–12**, which have been recently described as A β aggregation inhibitors (Figure 3).²⁷




Figure 3. *N*-Phenylantranilates reported in literature that inhibit $A\beta$ aggregation.

Thus, in the present study we describe a series of novel *N*-arylnaphthylamines (4–7) and thio analogues 8 and 9 (Figure 2 and Table 1) as potential inhibitors of $A\beta$ aggregation in *in vitro* assays, using the ThT.²⁴

As typical substituents *R* and *R*₁ (see Table 1), hydroxyls and carboxylic acids, including salicylic moieties, were chosen to mimic substituents that characterize compounds 1–3 and 10–12. Some replacement groups were also attempted to better define the SAR within this class of inhibitors. Furthermore, since the blood–brain barrier crossing always represents one of the main problems for the compounds aimed at acting on the central nervous system, we also performed *in vivo* preliminary studies on mice and assessed the ability of the most interesting inhibitor to cross the blood–brain barrier.

RESULTS AND DISCUSSION

Chemistry. Analysis. Mixture 1 as furnished by Aldrich (mordant black 1324-21-6), was analyzed by LC–MS using a RP18 column and ESI-MS detector. Various peaks were found, and the main one was quantified to represent around 40% of the mixture based on UV detection. After separation by semipreparative HPLC by means of a 1 cm RP18 column, this component was unequivocally identified to be 4a,9a-dihydro-3,4-dihydroxy-1-[1-(4-sulfophenylamino)]anthracene-9,10-dione (2) by NMR and MS analyses.

Synthesis. Syntheses of compounds 4–7 have been made through *N*-arylation of a substituted naphthylamine with the appropriate aryl halide by means of the Buchwald palladium-catalyzed amination reaction using a mixture of palladium acetate (Pd(OAc)₂) and racemic 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) as catalysts, in the presence of Cs₂CO₃. Thus, *N*-arylnaphthylamines 4b,m,o–r,t, 5c, and 6d,f,g have been synthesized in the cited conditions (Scheme 1). The above-described reaction performed on 4-nitro-1-naphthalenamine with 4-bromoanisole as electrophile agent gave very poor yield (<5%) because of the low reactivity of the deactivated naphthalenamine. Thus, we decided to invert the reactivity of the reagents using 4-iodo-1-nitronaphthalene as electrophile and 4-methoxyaniline as nucleophile agents, obtaining nitro derivative 4e in good yields (Scheme 1). This approach was also used for compounds 4c,d,f using the appropriate bromonaphthalene derivative and the properly substituted aniline (Scheme 1).

Deprotection of methoxy groups of 4m,q, and 6d was performed with BBr₃ at –45 °C to furnish 4g,k and 6a, respectively (Scheme 2).

The same reaction was used to deprotect methoxy and/or carboxymethyl groups of 4o,t, 5c, and 6f to furnish 4i,j,l, 5a,b, and 6b,c, respectively (Schemes 2 and 3).

Partial deprotection was obtained by performing the reaction at a controlled temperature. In fact, the methoxy group of compound 4o was selectively deprotected at –45 °C to give the corresponding phenol 4j. Conversely, when the temperature of the reaction was increased to room temperature with a longer reaction time (15 h), the carboxymethyl group was deprotected as well to obtain 4i (Scheme 3). However, a more convenient

route to obtain both hydroxy ester and hydroxy acid derivatives was found by performing the reaction at room temperature with a short reaction time (~30 min). In such a way, deprotection of 5c and 6f gave a mixture of 5a, 5b and 6b, 6c, respectively, which were separated by chromatography (Schemes 2 and 3). Further, the deprotection of 4t at room temperature for 15 h gave only the salicylic derivative 4l (Scheme 2).

Carboxylic acids 4a,n,s and 6e were obtained by basic hydrolysis of the corresponding esters 4b,o,t and 6f (Scheme 3).

Finally, the carbinol 4h was obtained starting from the corresponding methyl ester 4j by reduction with LiAlH₄ (Scheme 2). Unfortunately, derivative 4h was unstable and degraded rapidly after workup of the reaction.

Bis-naphthylamines 7 were obtained through a route similar to that described for compounds 4 and 6. In particular, *N*-arylation was performed starting from 1-bromo-2-methoxynaphthalene and 2-methoxy-1-naphthalenamine in the presence of Pd(OAc)₂, BINAP, and Cs₂CO₃. The bis-naphthylamine 7b that formed was then deprotected using BBr₃ to afford 7a, which proved to be unstable (Scheme 4).


The synthesis of thio derivatives 8 and 9 is reported in Scheme 5. The arylation step was obtained by palladium catalyzed reaction of 4-methoxythiophenol, using 1-iodo-4-methoxynaphthalene as arylating agent in the presence of tris(dibenzylideneacetone)dipalladium (Pd₂dba₃) and bis(2-diphenylphosphinophenyl) ether (DPEphos) as catalysts and *t*-BuOK (Scheme 5). This reaction afforded derivative 8b, which was deprotected in the presence of BBr₃ to furnish the phenol 8a or oxidized to afford sulfone 9b, which was in turn deprotected to give the phenol 9a.

Evaluation of Biological Activities. In Vitro Assays.

The antiaggregating activity of compounds 4–9 on the peptide $A\beta_{(1-42)}$ has been determined via the binding of the ThT according to the following procedure and is reported in more detail in the Experimental Section. Test compounds were added in the wells containing both the aggregate and the nonaggregate $A\beta_{(1-42)}$, incubated at 37 °C under agitation for 24 h. ThT was added to each well, and the fluorescence was measured. The assay was performed in triplicate in 96-well plates, and the data obtained were expressed as the dose reducing the aggregate formation by 50% (IC₅₀) (Table 1).

Among the 36 newly synthesized arylamines 4–9, 29 compounds were tested as reported above. The remaining compounds were not submitted to the ThT assay, since two compounds (4h and 7a) were unstable and five derivatives (4m,o, 6c, 8b, 9b) had poor solubility in the assay conditions. Derivatives 4a–d,n,p,r–t, 5b,c, 6e–g, and 9a were found to be inactive when tested at the highest concentration allowed by their solubility. Conversely, the remaining 14 compounds showed IC₅₀ ranging from 1 to 57.4 μM. In particular, nine compounds (4e–g,j,k,q, 6a,b, and 7b) were active at micromolar concentrations (IC₅₀ ranging from 1 to 5.7 μM), with the dihydroxy derivative 4k being the most potent one within this series, with IC₅₀ = 1 μM being comparable to the ones of alizarin derivative 2 and antranilates 11 and 12 and 38 times more potent than pamoate 3.

Table 1. Antiaggregating Activity of 4a–t, 5a–c, 6a–g, 7a,b, 8a,b, 9a,b, and Reference Compounds 2, 3, and 10–12 on the Peptide A β

			
compd	R	R ₁	IC ₅₀ (μM) ^a
4n	OCH ₃	4-COOH	>60
4o	OCH ₃	4-COOCH ₃	ND
4p	OCH ₃	2-OCH ₃	>5
4q	OCH ₃	4-OCH ₃	5.6
4r	OCH ₃	2-OCH ₃ -5-I	>5
4s	OCH ₃	3-COOH-4-OCH ₃	>80
4t	OCH ₃	3-COOCH ₃ -4-OCH ₃	ND
5a	OH	COOH	14.1
5b	OH	COOCH ₃	>20
5c	OCH ₃	COOCH ₃	>5
6a	OH	H	2.4
6b	OH	COOH	2.6
6c	OH	COOCH ₃	ND
6d	OCH ₃	H	33.6
6e	OCH ₃	COOH	>20
6f	OCH ₃	COOCH ₃	>20
6g	OCH ₃	I	>5
7a	OH	OH	ND
7b	OCH ₃	OCH ₃	5.7
8a	OH	OH	10.9
8b	OCH ₃	OCH ₃	ND
9a	OH	OH	>100
9b	OCH ₃	OCH ₃	ND
2			1.1
3			38.2
10			0.1
11			1
12			2

^aInhibitory concentration, 50% (μM), determined from dose–response curves. Experiments were performed in triplicate.

Removal of the phenolic OH group of 4k or its replacement with COOCH₃ led to arylamines 4g and 4j, which were about 5-fold less potent than the parent compound (4g, IC₅₀ = 5.4 μM; 4j, IC₅₀ = 5.1 μM). Conversely, its replacement with a COOH (4i) or transformation in a salicylic derivative (4l) gave a more substantial drop in activity (4i, IC₅₀ = 57.4 μM; 4l, IC₅₀ = 46.1 μM).

Replacement of both hydroxyls of 4k with OCH₃ groups led to naphthylarylamines 4q, which was about 5-fold less potent than the parent compound (IC₅₀ = 5.6 μM). However, generally the methylation of OH gave inactive compounds or compounds with low activity (compare 4g,i–l with 4m–t).

Compounds with no hydroxyl groups such as 4a–d were inactive. In particular, replacement of the OH of 4k with a fluorine atom led to fluoroderivative 4c that showed IC₅₀ > 30 μM.

The methylthiofluoro derivative 4d was inactive as well, while the corresponding compound 4f, in which the fluorine atom was replaced by a dimethylamino group, showed very good potency (IC₅₀ = 2.2 μM).

Although the presence of OH groups seems to be relevant for activity, it is not vital because its replacement with groups such as COOH, COOCH₃, OCH₃, NO₂, N(CH₃)₂, SCH₃ led to compounds active in the micromolar range (compare 4k with 4e–g,j,q, and 6a,b).


Shift of substituents of 4i from the 4- to 2-position of the aromatic rings led to 5a, which was 4-fold more potent than 4i (4i, IC₅₀ = 57.4 μM; 5a, IC₅₀ = 14.1 μM). However, introduction of less polar groups within the series of

compounds 5 gave results similar to those obtained for series 4, giving inactive derivatives 5b,c.


Compound 6a, the isomer of 4g in which the 4-hydroxyphenylamino moiety is transposed from the 4- to 2-position of the naphthalene ring, was about 2 times more potent than the parent compound (4g, IC₅₀ = 5.4 μM; 6a, IC₅₀ = 2.4 μM). An even stronger effect was obtained for the corresponding acid derivatives 4i and 6b. In fact, compound 6b showed IC₅₀ = 2.6 μM and was 22 times more active than 4i (IC₅₀ = 57.4 μM). Interestingly, introduction of a carboxylic group in the 4-position of the phenyl ring of 6a gave 6b, which was equipotent to the parent compound (6a, IC₅₀ = 2.4 μM; 6b, IC₅₀ = 2.6 μM). Conversely, a similar modification in the 4 series gave 4i that was about 10-fold less potent than 4g (4i, IC₅₀ = 57.4 μM; 4g, IC₅₀ = 5.4 μM). As confirmation of a general rule, phenol derivatives of the 6 series were more potent if compared to the less polar counterparts (see 6a,b and 6d–g).

Replacement of the phenyl ring of 4q with a naphthalene moiety gave the equipotent bis-naphthalenylamino derivative 7b (4q, IC₅₀ = 5.6 μM; 7b, IC₅₀ = 5.7 μM). No comparison was possible between the corresponding dihydroxyderivatives 4k and 7a, since the bis-naphtholamine derivative 7a was unstable.

Isosteric substitution of the linker of 4k with replacement of NH with a sulfur atom gave compound 8a, which was 11 times less active than the corresponding amine (4k, IC₅₀ = 1 μM; 8a, IC₅₀ = 10.9 μM). The oxidation of the linker of 8a led to the inactive sulphone 9a. Finally, both the dimethoxy derivatives 8b and 9b were too scarcely soluble to be tested.

Scheme 1^a

^aReagents and conditions: (i) Pd(OAc)₂, (±)-BINAP, Cs₂CO₃, 80 °C. For substituents R and R₁, see Table 1.

Scheme 2^a

^aReagents and conditions: (i) BBr₃, CH₂Cl₂, -45 °C; (ii) BBr₃, CH₂Cl₂, rt, 15 h; (iii) BBr₃, CH₂Cl₂, rt, 30 min; (iv) LiAlH₄, THF, rt. For substituents R₁, see Table 1.

Brain-to-Plasma Distribution Studies. The aim of these animal model studies was to evaluate the distribution between brain and plasma of *N*-arylnaphthylamines. Compound **4q** was selected as a representative derivative of the series because of a good balance between activity and lipophilicity as well as acceptable chemical stability. However, **4k**, which was the most potent compound within this series and proved to be 5–6 times more potent than **4q** in in vitro assays, showed oxidative degradation.

Figure 4 shows the plasma and brain concentration–time curves of compound **4q** after subcutaneous dosing in mice. Subcutaneous absorption was relatively rapid as indicated by the *t*_{max}, which was 60 min after a 25 mg/kg dose (dissolved in ethanol, PEG-400, saline, 10:40:50 v/v/v). The *C*_{max} was 164 ng/mL (*n* = 3) and AUC_t was 850 ng/(mL·h). Plasma concentrations of **4q** fell slowly thereafter, about 80% of the plasma *C*_{max} remaining after 6 h. However, in these preliminary studies, plasma sampling was not sufficiently long for a proper determination of half-life and of other conventional pharmacokinetic parameters.

From the plasma concentration–time curve, the compound achieved brain *C*_{max} at 60 min. However, brain *C*_{max} (410 ng/mL; *n* = 3) was 2.5 times that in plasma, indicating concentration of this *N*-arylnaphthylamine derivative in brain tissue.

After the peak, mean brain concentrations remained consistently 1.7- to 2.5-fold the plasma concentrations within 6 h of dosing, yielding a mean brain-to-plasma AUC_t ratio of about 2. This led us to conclude that **4q**, one of the most potent derivatives of the present series, rapidly entered the mouse central nervous system and equilibrated between plasma and brain.


Compound **4q** was well tolerated, since no discomfort or side effects were observed.

CONCLUSIONS


On the basis of the knowledge that a few dyes like CR were able to inhibit the aggregation of Aβ fibrils, we performed a screening of a series of dyes. Mixture **1** was found to be active and its main component, anthraquinone derivative **2** which was isolated and unequivocally identified, was tested for its antiaggregating properties in in vitro assay. Interestingly, compound **2** showed good potency in inhibiting the fibrils association in the ThT assay (IC₅₀ = 1 μM). So a series of *N*-arylnaphthylamine derivatives (**4**–**7**) and thio analogues **8** and **9** were designed as Aβ aggregation inhibitors. A number of the newly synthesized compounds have been found to be active with IC₅₀ ranging from 1 to 57.4 μM. The most potent compounds showed IC₅₀ in the low micromolar range, comparable to that of hit compound **2**. Furthermore, these novel *N*-arylnaphthylamine derivatives are potentially less toxic than the anthraquinone derivative **2** and one of the more interesting derivatives (**4q**) rapidly crossed the blood–brain barrier and diffused within the central nervous system, achieving concentrations about twice those in plasma, looking at the whole brain exposure. This brain-to-plasma ratio was similar to that of donepezil (1.74–2.24), slightly lower than that of rivastigmine and tacrine in rats (about 3 and 5, respectively),^{28–30} but it remains to be clarified whether such observations reflect the true extent of brain distribution, since the plasma protein binding of **4q** was not evaluated in this study. So **4q** represents a very interesting compound that could be developed with the aim to find new potent antiaggregating Aβ agents useful for the treatment of Alzheimer disease as well as other neurological diseases characterized by deposits of amyloid aggregates.

EXPERIMENTAL SECTION

Chemistry. General. Melting points were determined on a Bibby Stuart Scientific SMP1 melting point apparatus and are uncorrected. The purity of the compounds was always >95% as determined by high pressure liquid chromatography (HPLC). HPLC analyses were carried

Scheme 3^a


^aReagents and conditions: (i) BBr₃, CH₂Cl₂, -45 °C, 1 h; (ii) BBr₃, CH₂Cl₂, rt, 15 h; (iii) NaOH, THF/MeOH 1:1, reflux; (iv) BBr₃, CH₂Cl₂, rt, 35 min.

Scheme 4^a

^aReagents and conditions: (i) Pd(OAc)₂, (±)-BINAP, Cs₂CO₃, 80 °C; (ii) BBr₃, CH₂Cl₂, -45 °C.

out with a pump/autosampler Waters (Alliance model 2695), a UV photodiode array detector Waters (model 2996), and a system data management Waters (Empower 2). The column used was generally Suplex pkb-100 (250 mm × 4.6 mm, 5 μm). Infrared (IR) spectra (Nujol mulls) were recorded on a Perkin-Elmer Spectrum-One spectrophotometer. ¹H NMR spectra were recorded at 400 MHz on a Bruker AC 400 Ultrashield 10 spectrophotometer (400 MHz) and on Varian Gemini 200 and Varian XL 300 spectrometers (200 and 300 MHz, respectively). The LC-MS analyses have been performed with instrumentation equipped with HPLC-MS Thermo-Finnigan Surveyor LC pump, PDA detector, and single quadrupole MSQ detector.

Dimethylsulfoxide-*d*₆, 99.9% (code 44,139-2), and deuteriochloroform, 98.8% (code 41,675-4), of isotopic purity (Aldrich) were used as NMR solvents. Column chromatographies were performed on silica gel (Merck, 70–230 mesh). All compounds were routinely checked by TLC by using aluminum-baked silica gel plates (Fluka DC-Alufolien Kieselgel 60 F254). Plates were visualized by UV light. Solvents were reagent grade and, when necessary, purified and dried by standard methods. Concentration of solutions after reactions and extractions involved the use of rotary evaporator (Büchi) operating at a reduced pressure (~20 Torr). Organic solutions were dried over anhydrous sodium sulfate (Merck).

Scheme 5^a

^aReagents and conditions: (i) Pd₂dba₃, DPEphos, *t*-BuOK, 100 °C; (ii) BBr₃, THF, −45 °C, 2 h; (iii) Oxone, water, rt, 16 h; (iv) BBr₃, THF, 20 h, rt.




Figure 4. Mean plasma and brain concentration–time curves of compound **4q** after 25 mg/kg subcutaneous injection in mice. Each value is the mean \pm SD of three determinations for plasma (plain circles) and brain (empty circles).

Analyses. 4a,9a-Dihydro-3,4-dihydroxy-1-[1-(4-sulfophenylamino)]-anthracene-9,10-dione (**2**) isolated by mixture **1** (Aldrich, mordant black 1324-21-6) was analyzed by LC–MS. The major component showed negative ion ESI–MS: calcd for C₂₀H₁₂NO₇S [*M* − 1] 410.4, found 409.6.

A chromatographic separation was done on a semipreparative column Waters Xterra C18, 10 mm \times 100 mm, 5 μ m, under reversed phase conditions with a mobile phase consisting of A (AcONH₄ 10 mM/CH₃CN 80/20), B (AcONH₄ 10 mM/CH₃CN 60/40) under gradient conditions from 100% to 0% of A in 20 min, delivered at a flow rate of 1.00 mL/min, with ultraviolet detection at 280 nm. The column temperature was set at 25 °C, and the main component of the mixture (C₂₀H₁₂NO₇S [*M* − 1] 410.4) was isolated, **2**. ¹H NMR (DMSO-*d*₆) δ 6.58 (s, 1H, anthracene C2–H), 7.31 (d, 2H, *J*_o = 10.8 Hz, benzene H), 7.63 (d, 2H, *J*_o = 10.8 Hz, benzene H), 7.89 (t, 2H, *J*_o = 9.6 Hz, anthracene C6–H and anthracene C7–H), 8.25 (dd, 2H, *J*_o = 9.6 Hz, anthracene C5–H and anthracene C8–H), 9.19 (s, 1H, NH). Anal. (C₂₀H₁₃NO₇S) C, H, N, S.

Syntheses. General Procedure for the Synthesis of *N*-Arylnaphthylamines 4b,m,o–r,t, 5c, 6d,f,g, and 7b. A dried flask was purged with argon, charged with (\pm)-BINAP (0.11 mmol), and capped with rubber septum. The flask was purged with argon again, and toluene (9.7 mL) was added. The mixture was heated to 80 °C under stirring until BINAP dissolved (1 min). The solution was cooled to room temperature, and Pd(OAc)₂ (0.07 mmol) was added. The

flask was then purged with argon for 30 s. After the mixture was stirred at room temperature for 1 min, a solution of substituted naphthylamine (3.5 mmol) and appropriate aryl halide in toluene (1.5 mL) was added. Then Cs₂CO₃ (4.0 mmol) was introduced within the mixture which was then diluted with toluene (7 mL) and then purged with argon again. The mixture was heated to 80 °C under stirring and was cooled to room temperature before being diluted with ether, filtered, and concentrated. The crude product obtained was purified by column chromatography. Reagents, reaction time, eluent of chromatography, yield (%), melting point (°C), recrystallization solvent, IR, ¹H NMR, and analytical data are reported for each of the following compounds.

Methyl 4-(1-Naphthylamino)benzoate (4b). 1-Naphthalenamine and methyl 4-bromobenzoate; 16 h; chloroform/petroleum ether 3:1; 96%; 130–132 °C; toluene. IR ν 3340 (NH), 1694 (CO) cm^{−1}. ¹H NMR (DMSO-*d*₆) δ 3.79 (s, 3H, CH₃), 6.95 (m, 2H, benzene C3–H and C5–H), 7.45–7.60 (m, 4H, naphthalene H), 7.73 (m, 1H, naphthalene H), 7.79 (m, 2H, benzene C2–H and C6–H), 7.98 (m, 1H, naphthalene H), 8.06 (m, 1H, naphthalene H), 8.88 (s broad, 1H, NH). Anal. (C₁₈H₁₅NO₂) C, H, N, O.

4-Methoxy-*N*-phenyl-1-naphthalenamine (4m). 4-Methoxy-1-naphthalenamine³¹ and bromobenzene; 21 h; ethyl acetate/*n*-hexane 1:1; 70%; 141–143 °C; cyclohexane/*n*-hexane. IR ν 3400 (NH) cm^{−1}. ¹H NMR (CDCl₃) δ 4.07 (s, 3H, CH₃), 5.75 (s broad, 1H, NH), 6.75–6.90 (m, 4H, naphthalene H and benzene C2–H and C6–H), 7.15–7.25 (m, 3H, benzene C3–H, C4–H, and C5–H), 7.50–7.60 (m, 2H, naphthalene H), 8.04 (m, 1H, naphthalene H), 8.33 (m, 1H, naphthalene H). Anal. (C₁₇H₁₅NO) C, H, N.

Methyl 4-[(4-Methoxynaphthalen-1-yl)amino]benzoate (4o). 4-Methoxy-1-naphthalenamine³¹ and methyl 4-bromobenzoate; 24 h; ethyl acetate/*n*-hexane 1:1; 77%; 168–170 °C; benzene. IR ν 3300 (NH) cm^{−1}. ¹H NMR (CDCl₃) δ 3.89 (s, 3H, COOCH₃), 4.08 (s, 3H, OCH₃), 6.03 (s broad, 1H, NH), 6.45–6.71 (m, 2H, benzene C3–H and C5–H), 6.85 (d, *J*_o = 8.1 Hz, naphthalene H), 7.39 (d, *J*_o = 8.1 Hz, naphthalene H), 7.48–7.61 (m, 2H, naphthalene H), 7.85–7.96 (m, 3H, naphthalene H and benzene C2–H and C6–H), 8.35–8.41 (m, 1H, naphthalene H). Anal. (C₁₉H₁₇NO₃) C, H, N, O.

***N*-(4-Methoxy-1-naphthyl)-*N*-(2-methoxyphenyl)amine (4p).** 4-Methoxy-1-naphthalenamine³¹ and 2-methoxy-1-bromobenzene; 39 h; ethyl acetate/*n*-hexane 1:2; 70%; 108–110 °C; cyclohexane. IR ν 3395 (NH) cm^{−1}. ¹H NMR (CDCl₃) δ 3.98 and 4.02 (2s, 6H, CH₃), 6.60 and 6.91 (2 m, 2H, benzene C3–H and C6–H), 6.73 (m, 2H, benzene C4–H and C5–H), 6.80 (d, 1H, *J*_o = 8.1 Hz, naphthalene C2–H), 7.35 (d, 1H, *J*_o = 8.1 Hz, naphthalene C3–H), 7.48 (m, 2H, naphthalene C6–H and C7–H), 7.98 and 8.03 (2 m, 2H, naphthalene C5–H and C8–H). Anal. (C₁₈H₁₇NO₂) C, H, N.

4-Methoxy-*N*-(4-methoxyphenyl)-1-naphthalenamine (4q). 4-Methoxy-1-naphthalenamine³¹ and 4-methoxy-1-bromobenzene; 21 h; ethyl acetate/*n*-hexane 1:1; 96%; oil. IR ν 3380 (NH) cm^{-1} . ^1H NMR (CDCl_3) δ 3.81 and 4.04 (2s, 6H, CH_3), 5.90 (s broad, 1H, NH), 6.74–6.85 (m, 6H, naphthalene C2–H and C3–H and benzene H), 7.51–7.58 (m, 2H, naphthalene H), 8.04 (m, 1H, naphthalene H), 8.35 (m, 1H, naphthalene H). Anal. ($\text{C}_{18}\text{H}_{17}\text{NO}_2$) C, H, N.

***N*-(5-Iodo-2-methoxyphenyl)-*N*-(4-methoxy)-1-naphthylamine (4r).** 4-Methoxy-1-naphthalenamine³¹ and 2,4-diiodoanisole; 48 h; flash chromatography ethyl acetate/*n*-hexane 1:20; 18%; oil. IR ν 3390 (NH) cm^{-1} . ^1H NMR (CDCl_3) δ 3.95 and 4.03 (2s, 6H, CH_3), 6.61 (d, 1H, $J_o = 8.1$ Hz, benzene C3–H), 6.78 (d, 1H, $J_m = 2.0$ Hz, benzene C6–H), 6.82 (d, 1H, $J_o = 8.1$ Hz, naphthalene C3–H), 7.01 (dd, 1H, $J_o = 8.3$ Hz, $J_m = 2.0$ Hz, benzene C4–H), 7.34 (d, 1H, $J_o = 8.1$ Hz, naphthalene C2–H), 7.50 (m, 2H, naphthalene C6–H and C7–H), 7.92 and 8.31 (2 m, 2H, naphthalene C5–H and C8–H). Anal. ($\text{C}_{18}\text{H}_{16}\text{NO}_2\text{I}$) C, H, N, I.

Methyl 2-(Methoxymethyl)-5-[(4-methoxynaphthalen-1-yl)amino]benzoate (4t). 4-Methoxy-1-naphthalenamine³¹ (9.1 mmol) and methyl 2-methoxy-5-bromobenzoate using (\pm) BINAP (0.76 mmol), $\text{Pd}(\text{OAc})_2$ (0.51 mmol); 120 $^\circ\text{C}$; 24 h; ethyl acetate/*n*-hexane 1:1; 97%; oil. IR ν 3320 (NH), 1695 (CO) cm^{-1} . ^1H NMR (CDCl_3) δ 3.88 (2s, 3H, CH_3), 3.89 (s, 3H, OCH_3), 4.04 (s, 3H, OCH_3), 5.60 (s broad, 1H, NH), 6.79 (d, 1H, $J = 8.2$ Hz, naphthalene H), 6.88 (m, 2H, benzene C5–H and C6–H), 7.22 (d, 1H, $J = 8.2$ Hz, naphthalene H), 7.34 (m, 1H, benzene C2–H), 7.50–7.58 (m, 2H, naphthalene H), 7.99 and 8.34 (2 m, 2H, naphthalene H).

Methyl 2-[(2-Methoxy-1-naphthyl)amino]benzoate (5c). 2-Methoxy-1-naphthalenamine³² and methyl-2-bromobenzoate; 15.5 h; ethyl acetate/*n*-hexane 1:5; 100%; 144–146 $^\circ\text{C}$. IR ν 3321 (NH), 1681 (CO) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 3.86 (s, 3H, CH_3), 3.89 (s, 3H, CH_3), 6.09 (m, 1H, benzene H), 6.66 (m, 1H, benzene H), 7.18 (m, 1H, naphthalene H), 7.35–7.45 (m, 2H, benzene H and naphthalene H), 7.57 (m, 1H, naphthalene H), 7.68 (m, 1H, benzene H), 7.88–7.95 (m, 3H, naphthalene H), 9.17 (s broad, 1H, NH). Anal. ($\text{C}_{19}\text{H}_{17}\text{NO}_3$) C, H, N.

(1-Methoxy-2-naphthyl)phenylamine (6d). 1-Methoxy-2-naphthalenamine³³ and bromobenzene; 16 h; ethyl acetate/*n*-hexane 1:1; 83%; 43–45 $^\circ\text{C}$; *n*-hexane. IR ν 3395 (NH) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 3.80 (s, 3H, CH_3), 6.85 (m, 1H, benzene H), 7.07–7.65 (m, 8H, naphthalene H and benzene H), 7.84 (m, 1H, naphthalene H), 7.93 (s broad, 1H, NH), 7.99 (m, 1H, naphthalene H). Anal. ($\text{C}_{17}\text{H}_{15}\text{NO}$) C, H, N.

Methyl 4-(1-Methoxy-2-naphthylamino)benzoate (6f). 1-Methoxy-2-naphthalenamine³³ and methyl 4-bromobenzoate; 4 h and 10 min; chloroform/ethyl acetate 9:1; 97%; 153–154 $^\circ\text{C}$; ligroin. IR ν 3327 (NH), 1691 (CO) cm^{-1} . ^1H NMR (CDCl_3) δ 3.95 (s, 3H, CH_3), 7.14 (d, 2H, $J_o = 8.8$ Hz, benzene C2–H and C6–H), 7.44–7.48 (m, 2H, naphthalene H), 7.55–7.59 (m, 1H, naphthalene H), 7.64–7.69 (m, 2H, naphthalene H), 8.03 (d, 2H, $J_o = 8.8$ Hz, benzene C3–H and C5–H), 8.10 (m, 1H, naphthalene H). Anal. ($\text{C}_{19}\text{H}_{17}\text{NO}_3$) C, H, N.

***N*-(4-Iodophenyl)-1-methoxynaphthalen-2-amine (6g).** 1-Methoxy-2-naphthalenamine³³ and 1,4-diiodobenzene; 19 h; 37%; 83–84 $^\circ\text{C}$; *n*-hexane. IR ν 3327 (NH) cm^{-1} . ^1H NMR (CDCl_3) δ 3.96 (s, 3H, CH_3), 6.97 (d, 2H, $J_o = 8.8$ Hz, benzene C2–H and C6–H), 7.40–7.43 (m, 1H, naphthalene H), 7.53–7.57 (d, 2H, $J_o = 8.8$ Hz, benzene C3–H and C5–H), 7.61–7.74 (m, 3H, naphthalene H), 7.83–7.85 (m, 1H, naphthalene H), 8.06–8.08 (m, 1H, naphthalene H). Anal. ($\text{C}_{19}\text{H}_{14}\text{NIO}$) C, H, N, I.

2-Methoxy-*N*-(2-methoxy-1-naphthyl)naphthalen-1-amine (7b). 2-Methoxy-1-naphthalenamine³² and 2-methoxy-1-bromonaphthalene; ethyl acetate/*n*-hexane 1:5; 59%; oil. IR ν 3380 (NH) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 3.55 (s, 6H, CH_3), 7.05 (s broad, 1H, NH), 7.20–7.38 (m, 6H, naphthalene H), 7.58 (m, 2H, naphthalene H), 7.81–7.93 (m, 4H, naphthalene H). Anal. ($\text{C}_{22}\text{H}_{20}\text{NO}_2$) C, H, N.

General Procedure for the Synthesis of *N*-Arylnaphthylamines 4c–f. A dried flask was purged with argon, charged with (\pm)-BINAP (0.11 mmol), and capped with rubber septum. The flask was purged with argon again, and toluene (9.7 mL) was added. The

mixture was heated to 80 $^\circ\text{C}$ under stirring until the BINAP was dissolved (1 min). The solution was cooled to room temperature, and $\text{Pd}(\text{OAc})_2$ (0.07 mmol) was added. The flask was then purged with argon for 30 s. After stirring of the mixture at room temperature for 1 min, a solution of 4-halo-1-substituted naphthalene (3.5 mmol) with appropriate 4-substituted aniline (2.9 mmol) in toluene (1.5 mL) was added. Cs_2CO_3 (4.0 mmol) was introduced within the mixture. Toluene (7 mL) was added and then the flask purged with argon again. The mixture was heated to 80 $^\circ\text{C}$ under stirring, then was cooled to room temperature, diluted with ether, filtered, and concentrated. The crude product that was obtained was purified by column chromatography to obtain the desired adduct. Reagents, reaction time, eluent of chromatography, yield (%), melting point ($^\circ\text{C}$), recrystallization solvent, IR, ^1H NMR, and analytical data are reported for each of the following compounds.

4-Fluoro-*N*-(4-fluorophenyl)naphthalen-1-amine (4c). 4-Fluoroaniline and 1-bromo-4-nitronaphthalene; 5 h and 45 min; chloroform; 91%; 62–64 $^\circ\text{C}$; *n*-hexane. IR ν 3395 (NH) cm^{-1} . ^1H NMR (CDCl_3) δ 5.55 (s broad, 1H, NH), 6.89–6.90 (m, 2H, benzene H), 6.98–7.03 (m, 2H, benzene H), 7.11–7.17 (m, 1H, naphthalene C2–H), 7.24 (m, 1H, naphthalene C3–H), 7.57–7.66 (m, 2H, naphthalene C6–H and C7–H), 8.05 and 8.20 (2 m, 2H, naphthalene C5–H and C8–H). Anal. ($\text{C}_{16}\text{H}_{11}\text{NF}_2$) C, H, N, F.

4-Fluoro-*N*-[4-(methylthio)phenyl]naphthalen-1-amine (4d). 1-(Methylthio)aniline and 1-bromo-4-fluoronaphthalene; 17 h; chloroform/petroleum ether 1:1; 94%; 71–72 $^\circ\text{C}$; *n*-hexane. IR ν 3337 (NH) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 2.44 (s, 3H, SCH_3), 6.93 (d, 2H, $J_o = 8.7$ Hz, benzene C3–H and C5–H), 7.20–7.33 (d, 2H, $J_o = 8.7$ Hz, benzene C2–H and C3–H), 7.63–7.71 (m, 2H, naphthalene C6–H and C7–H), 8.07 and 8.18 (2 m, 2H, naphthalene C5–H and C8–H), 8.21 (s broad, 1H, NH). Anal. ($\text{C}_{17}\text{H}_{14}\text{NFS}$) C, H, N, F, S.

***N*-(4-Methoxyphenyl)-4-nitronaphthalen-1-amine (4e).** 4-Iodo-1-nitronaphthalene³⁴ and 4-methoxyaniline; chloroform; 15 h; 38%; oil. IR ν 3365 (NH) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 3.93 (s, 3H, CH_3), 6.85 (s broad, 1H, NH), 6.80 (m, 1H, naphthalene H), 7.05 (d, 2H, $J_o = 8.8$ Hz, benzene C3–H and C5–H), 7.30 (d, 2H, $J_o = 8.8$ Hz, benzene C2–H and C6–H), 7.67–7.81 (2 m, 2H, naphthalene C6–H and C7–H), 8.08, 8.39, and 9.07 (3 m, 3H, naphthalene C2–H, C5–H, and C8–H). Anal. ($\text{C}_{17}\text{H}_{14}\text{N}_2\text{O}_3$) C, H, N.

***N,N*-Dimethyl-*N'*-[4-(methylthio)phenyl]naphthalene-1,4-diamine (4f).** 4-(Methylthio)aniline and 1-bromo-4-(dimethylamino)naphthalene; 16 h; chloroform; 81%; oil. IR ν 3381 (NH) cm^{-1} . ^1H NMR ($\text{DMSO}-d_6$) δ 2.42 (s, 3H, SCH_3), 2.84 (s, 6H, NCH_3), 6.86 (d, 2H, $J_o = 8.8$ Hz, benzene C2–H and C6–H), 7.14–7.20 (m, 3H, $J_o = 8.8$ Hz, naphthalene H and benzene C3–H and C5–H), 7.56 (m, 2H, naphthalene C2–H and C3–H), 8.07–8.09 (m, 2H, NH and naphthalene H), 8.23 (m, 1H, naphthalene H). Anal. ($\text{C}_{19}\text{H}_{20}\text{NS}$) C, H, N, S.

1-Methoxy-4-[(4-methoxyphenyl)thio]naphthalene (8b). A dried flask was charged with Pd_2dba_3 (130 mg, 0.141 mmol), dissolved in degassed toluene (115 mL), treated with DPEphos (150 mg, 0.28 mmol), and purged with argon. The mixture was stirred at room temperature for 3 min. Then 1-methoxy-4-iodonaphthalene (4.0 g, 14.1 mmol) and 4-methoxythiophenol (2.0 g, 14.1 mmol) were added under argon atmosphere. *t*-BuOK (1.7 g, 15.5 mmol) was added and the flask purged with argon. The mixture was stirred for 2 h at 100 $^\circ\text{C}$, cooled to room temperature, and filtered on a Celite cake, and the filtrate was concentrated in vacuo. The crude product (6.2 g) was purified by column chromatography (*n*-hexane/acetone 10:1) to obtain the desired adduct as a slightly colored (3.6 g) solid, which was purified by recrystallization (*n*-hexane) to obtain 2.7 g of pure **8b** (65%): mp 83–85 $^\circ\text{C}$. IR ν 2937 (CH) cm^{-1} . ^1H NMR (acetone- d_6) δ 3.78 (s, 3H, CH_3), 4.10 (s, 3H, CH_3), 6.88 (d, 2H, $J_o = 8.86$ Hz, benzene H), 7.03 (d, 1H, $J_o = 8.01$ Hz, naphthalene C2–H), 7.20 (d, 2H, $J_o = 8.86$ Hz, benzene H), 7.57–7.64 (m, 2H, naphthalene C6–H and C7–H), 7.75 (d, 1H, $J_o = 8.01$ Hz, naphthalene C3–H), 8.34–8.40 (m, 2H, naphthalene C5–H and C8–H). Anal. ($\text{C}_{18}\text{H}_{16}\text{O}_2\text{S}$) C, H, N, S.

General Procedure for the Synthesis of Acids 4a,n,s and 6e. A solution of the appropriate methyl ester (1.5 mmol) and 1 N NaOH

(3.7 mL) in THF/ethanol 1:1 (20 mL) was refluxed for 3 h for **4a**, 3 h and 30 min for **4n,t**, and 1 h and 40 min for **6e**, while stirring. Then the mixture was poured into crushed ice and extracted with ethyl acetate (30 mL). The aqueous layer was treated with 1 N HCl until pH 3 and then extracted with ethyl acetate (3 × 50 mL). The organic phases were collected, washed with brine (3 × 100 mL), dried, and the solvent was removed under reduced pressure to yield the final product. Reagents, reaction time, eluent of chromatography, yield (%), melting point (°C), recrystallization solvent, IR, ¹H NMR, and analytical data are reported for each of the following compounds

4-(1-Naphthylamino)benzoic Acid (4a). **4b**; 3 h; 59%; 227–229 °C; toluene. IR ν 3390 (NH), 2900 (OH), 1670 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.95 (m, 2H, benzene C3–H and C5–H), 7.46–7.60 (m, 4H, naphthalene H), 7.72 (m, 1H, naphthalene H), 7.78 (m, 2H, benzene C2–H and C6–H), 7.96 (m, 1H, naphthalene H), 8.07 (m, 1H, naphthalene H), 8.81 (s broad, 1H, NH), 12.29 (s broad, 1H, OH). Anal. (C₁₇H₁₃NO₃) C, H, N.

4-(4-Methoxy-1-naphthylamino)benzoic Acid (4n). **4o**; 3.5 h; 50%; 153–154 °C; isopropanol. IR ν 3400 (NH), 3000 (OH), 1650 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 4.01 (s, 3H, CH₃), 6.70 (d, 2H, *J*_o = 8.5 Hz, benzene C3–H and C5–H), 7.01 (d, 1H, *J* = 8.0 Hz, naphthalene C3–H), 7.39 (d, 1H, *J* = 8.0 Hz, naphthalene C2–H), 7.55 (m, 2H, naphthalene C6–H and C7–H), 7.71 (d, 2H, *J*_o = 8.5 Hz, benzene C2–H and C6–H), 7.90 (m, 1H, naphthalene H), 8.20 (m, 1H, naphthalene H), 8.54 (s broad, 1H, NH). Anal. (C₁₈H₁₅NO₃) C, H, N.

2-Methoxy-5-(4-methoxy-1-naphthylamino)benzoic Acid (4s). **4t**; 3.5 h; 50%; 153–154 °C; isopropanol. IR ν 3300 (NH), 3160 (OH), 1690 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 3.76 (s, 3H, OCH₃), 3.97 (s, 3H, OCH₃), 6.91–6.98 (m, 3H, naphthalene H and benzene C3–H and C4–H), 7.16 (m, 1H, benzene C6–H), 7.21 (d, 1H, naphthalene H), 7.53 (m, 2H, naphthalene H), 7.76 (s broad, 1H, NH), 8.05 and 8.20 (2 m, 2H, naphthalene H), 12.50 (s broad, 1H, OH). Anal. (C₁₉H₁₇NO₄) C, H, N.

4-(1-Methoxy-2-naphthylamino)benzoic Acid (6e). **6f**; 1 h and 40 min; 100%; 233–235 °C; ethanol. IR ν 3403 (OH and NH), 1691 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 3.80 (s, 3H, CH₃), 7.01 (d, 2H, *J*_o = 8.6 Hz, benzene C2–H and C6–H), 7.46–7.59 (m, 3H, naphthalene H), 7.72 (m, 1H, naphthalene H), 7.82 (d, 2H, *J*_o = 8.6 Hz, benzene C3–H and C5–H), 7.93 (m, 1H, naphthalene H), 8.08 (m, 1H, naphthalene H), 8.59 (s broad, 1H, NH), 12.32 (s broad, 1H, COOH). Anal. (C₁₈H₁₅NO₃) C, H, N.

General Procedure for the Synthesis of Compounds 4g,i–l, 5a,b, 6a–c, 7a, 8a, and 9a. A solution of the proper *N*-phenyl-1-naphthalenamine derivative **4m,o,q,t**, **5c**, **6d,f**, **7b**, **8b**, or **9b** (2.4 mmol) in dichloromethane (27 mL) was added dropwise to 1 M BBr₃ (12.6 mL, 12.6 mmol) in the same solvent at –45 °C under argon atmosphere while stirring. After being diluted with water (50 mL), the mixture was extracted with ethyl acetate (3 × 50 mL) and the organic phases were collected, washed with brine (3 × 100 mL), and dried. Evaporation of the solvent gave a crude product, which was chromatographed to afford pure product(s). Substrate, reaction temperature, reaction time, eluent of chromatography, yield (%), melting point (°C), recrystallization solvent, IR, ¹H NMR, and analytical data are reported for each of the following compounds.

4-Phenylamino-naphthalen-1-ol (4g). **4m**; –45 °C under argon atmosphere; 15 h; ethyl acetate/*n*-hexane 1:3; 88%; oil. IR ν 3350 (OH, NH) cm⁻¹. ¹H NMR (CDCl₃) δ 5.30 and 5.65 (2s, broad, 2H, OH and NH), 6.75–6.87 (m, 4H, naphthalene H and benzene C2–H and C6–H), 7.15–7.30 (m, 3H, benzene C3–H, C4–H, and C5–H), 7.50–7.57 (m, 2H, naphthalene H), 8.50 (m, 1H, naphthalene H), 8.25 (m, 1H, naphthalene H). Anal. (C₁₆H₁₃NO) C, H, N.

4-(4-Hydroxy-1-naphthylamino)benzoic Acid (4i). **4o**; rt; 15 h; ethyl acetate/*n*-hexane 9:2; 45%; 214–217 °C; toluene. IR ν 3360 (OH, NH), 2800 (COOH) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.63 (d, 2H, *J*_o = 8.7 Hz, benzene C3–H and C5–H), 6.92 (d, 1H, *J* = 8.0 Hz, naphthalene H), 7.27 (d, 1H, *J* = 8.0 Hz, naphthalene H), 7.50 (m, 2H, naphthalene H), 7.69 (d, 2H, *J*_o = 8.7 Hz, benzene C2–H and C6–H), 7.85 (m, 1H, naphthalene H), 8.20 (m, 1H, naphthalene H),

8.45 (s broad, 1H, NH), 10.20 (s broad, 1H, OH), 12.15 (s broad, 1H, COOH). Anal. (C₁₇H₁₃NO₃) C, H, N.

Methyl 4-(4-Hydroxy-1-naphthylamino)benzoate (4j). **4o**; –45 °C; 1 h; ethyl acetate/*n*-hexane 1:2; 58%; 188–190 °C; benzene/*n*-hexane. IR ν 3377 (OH, NH), 1680 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 3.73 (s, 3H, CH₃), 6.60–6.67 (m, 2H, benzene C3–H and C5–H), 6.86–6.88 (d, 1H, *J* = 8.0 Hz, naphthalene H), 7.21–7.23 (d, 1H, *J* = 8.0 Hz, naphthalene H), 7.44–7.48 (m, 2H, naphthalene H), 7.65–7.67 (m, 2H, benzene C2–H and C6–H), 7.82 (m, 1H, naphthalene H), 8.17 (m, 1H, naphthalene H), 8.50 (s broad, 1H, NH), 10.18 (s broad, 1H, OH). Anal. (C₁₈H₁₅NO₃) C, H, N.

4-(4-Hydroxy-phenylamino)naphthalen-1-ol (4k). The solvent was purged with argon. **4q**; –45 °C; 15 h; ethyl acetate/*n*-hexane 1:1; 80%; 74 °C (dec). IR ν 3375 (OH, NH) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.55–7.00 (m, 7H, naphthalene H, benzene H and NH), 7.38–7.67 (m, 2H, naphthalene H), 7.95–8.13 (m, 2H, naphthalene H), 8.67 and 9.67 (2s broad, 2H, OH). Anal. (C₁₆H₁₃NO₂) C, H, N.

2-Hydroxy-5-(4-hydroxy-1-naphthylamino)benzoic Acid (4l). **4t**; rt; 15 h; ethyl acetate; 17%; 175 °C (dec). IR ν 3350 (OH, NH), 3000 (COOH), 1635 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.73 (d, 1H, *J*_o = 8.7 Hz, benzene C3–H), 6.82 (d, 1H, *J* = 8.0 Hz, naphthalene H), 6.97 (dd, 1H, *J*_o = 8.7 Hz, *J*_m = 2.7 Hz, benzene C4–H), 7.05 (d, 1H, *J* = 8.0 Hz, naphthalene H), 7.20 (d, 1H, *J*_m = 2.7 Hz, benzene C6–H), 7.44–7.49 (m, 2H, naphthalene C6–H and C7–H), 7.99 (m, 1H, naphthalene H), 8.15 (m, 1H, naphthalene H), 9.85 (3s broad, 3H, OH, COOH and NH). Anal. (C₁₇H₁₃NO₄) C, H, N.

2-(2-Hydroxy-1-naphthylamino)benzoic Acid (5a) and Methyl 2-(2-Hydroxy-1-naphthylamino)benzoate (5b). **5c**; rt; 23 min; ethyl acetate/*n*-hexane 1:2. **5a**: 55%; 215–216 °C; toluene. IR ν 3361 (OH and COOH), 3325 (NH), 1659 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.09 (m, 1H, benzene H), 6.62 (m, 1H, benzene H), 7.14 (m, 1H, naphthalene H), 7.28–7.31 (m, 2H, naphthalene H), 7.39 (m, 1H, benzene H), 7.62 (m, 1H, benzene H), 7.75 (m, 1H, naphthalene H), 7.83–7.89 (m, 2H, naphthalene H), 9.28 (s broad, 1H, NH), 12.86 (s broad, 1H, COOH). Anal. (C₁₇H₁₃NO₃) C, H, N. **5b**: 45%; 157–158 °C; cyclohexane. IR ν 3407 (OH and COOH), 3319 (NH), 1681 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 3.88 (s, 3H, CH₃), 6.10 (m, 1H, benzene H), 6.64 (m, 1H, benzene H), 7.17 (m, 1H, naphthalene H), 7.28–7.31 (m, 2H, naphthalene H), 7.39 (m, 1H, benzene H), 7.62 (m, 1H, benzene H), 7.77 (m, 1H, naphthalene H), 7.84–7.95 (m, 2H, naphthalene H), 9.05 (s broad, 1H, NH), 9.78 (s broad, 1H, OH). Anal. (C₁₈H₁₅NO₃) C, H, N.

1-Hydroxy-N-phenylnaphthalen-2-amine (6a). **6d**; –45 °C; 30 min; ethyl acetate/*n*-hexane 1:3; 88%; >300 °C. IR ν 3150 (NH and OH) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.70 (m, 1H, benzene H), 6.81–6.88 (m, 2H, benzene H), 7.07–7.16 (m, 2H, naphthalene H), 7.31–7.42 (m, 4H, benzene H and naphthalene H), 7.77 (m, 1H, naphthalene H), 8.11 (m, 1H, naphthalene H). Anal. (C₁₆H₁₃NO) C, H, N.

4-(1-Hydroxy-2-naphthylamino)benzoic Acid (6b) and Methyl 4-(1-Hydroxy-2-naphthylamino)benzoate (6c). **6f**; rt; 35 min; ethyl acetate/*n*-hexane 1:1. **6b**: 45%; 210 °C (dec); methanol. IR ν 3426 (OH and COOH), 3353 (NH), 1654 (CO) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 6.78–6.80 (m, 2H, benzene C2–H and C6–H), 7.33–7.36 (m, 1H, naphthalene H), 7.42–7.50 (m, 3H, naphthalene H), 7.74–7.77 (m, 2H, benzene C3–H and C5–H), 7.84–7.86 (m, 1H, naphthalene H), 8.18 (s broad, 1H, NH), 8.19–8.21 (m, 1H, naphthalene H), 9.40 (s broad, 1H, OH), 12.20 (s broad, 1H, COOH). Anal. (C₁₇H₁₃NO₃) C, H, N. **6c**: acetone/*n*-hexane 1:4; 55%; 175–176 °C; toluene. IR: ν 3334 (OH and NH) cm⁻¹. ¹H NMR (DMSO-*d*₆) δ 3.79 (s, 3H, CH₃), 7.28–7.31 (m, 2H, naphthalene H), 7.35 (m, 1H, naphthalene H), 7.39 (m, 2H, *J*_o = 8.8 Hz, benzene C2–H and C6–H), 7.45–7.51 (m, 3H, naphthalene H), 7.77 (m, 2H, *J*_o = 8.8 Hz, benzene C3–H and C5–H), 8.25 (s broad, 1H, NH), 9.40 (s broad, 1H, OH). Anal. (C₁₈H₁₅NO₃) C, H, N.

2-Hydroxy-N-(2-hydroxy-1-naphthyl)naphthalen-1-amine (7b). **7a**; –45 °C, rt; 15 h, ethyl acetate/*n*-hexane 1:2. After isolation the compound **7a** rapidly degraded so that no analytical and structural data are available.

4-[(4-Hydroxyphenyl)thio]-1-naphthol (**8a**). **8b**; -45°C , 15.5 h, then rt; 7 h; ethyl acetate/*n*-hexane 2:5; 61%; 161–163 $^{\circ}\text{C}$; toluene. IR ν 3255 (OH) cm^{-1} . ^1H NMR (DMSO- d_6) δ 6.70 (d, 2H, J_o = 8.69 Hz, benzene H), 6.93 (d, 1H, naphthalene C2–H), 7.06 (d, 2H, J_o = 8.69 Hz, benzene H), 7.51–7.62 (m, 3H, naphthalene C3–H, C6–H, and C7–H), 8.23 and 8.27 (2 m, 2H, naphthalene C5–H and C8–H), 9.52 and 10.61 (2s broad, 2H, OH). Anal. ($\text{C}_{16}\text{H}_{12}\text{O}_2\text{S}$) C, H, S.

4-[(4-Hydroxyphenyl)sulfonyl]-1-naphthol (**9a**). **9b**; -45°C , 20 min, then rt; 20 h; ethyl acetate/chloroform 1:2; 58%; 203–205 $^{\circ}\text{C}$; toluene. IR ν 3300 (OH) cm^{-1} . ^1H NMR (DMSO- d_6) δ 7.90 (d, 2H, J_o = 8.77 Hz, benzene H), 7.07 (d, 1H, J_o = 8.29 Hz, naphthalene C2–H), 7.58 and 7.67 (2 m, 2H, naphthalene C6–H and C7–H), 7.77 (d, 2H, J_o = 8.77 Hz, benzene H), 8.28–8.31 (m, 2H, naphthalene C5–H and C8–H), 8.48 (d, 1H, J_o = 8.29 Hz, naphthalene C3–H), 10.54 and 11.51 (2s broad, 2H, OH). Anal. ($\text{C}_{16}\text{H}_{12}\text{O}_4\text{S}$) C, H, S.

1-Methoxy-4-[(4-methoxyphenyl)sulfonyl]naphthalene (**9b**). **8b** (1 g, 3.4 mmol) was dissolved in methanol (84 mL). At 0°C a solution of Oxone (6.3 g, 10.2 mmol) in water (20 mL) was added. The mixture was stirred for 16 h at room temperature. The mixture was poured into water, extracted with ethyl acetate (3×100 mL), and the collected organic layers were washed with brine (3×100 mL) and dried over anhydrous Na_2SO_4 . The solvent was evaporated in vacuum, obtaining a crude product which was purified by column chromatography (chloroform as eluent) affording the pure product **9b** (82%); mp 165–167 $^{\circ}\text{C}$; toluene. IR ν 2900 (CH) cm^{-1} . ^1H NMR (DMSO- d_6) δ 3.82 (s, 3H, CH_3), 4.12 (s, 3H, CH_3), 7.11 (d, 2H, J_o = 8.69 Hz, benzene H), 7.25 (d, 1H, J_o = 8.47 Hz, naphthalene C2–H), 7.64 and 7.72 (2 m, 2H, naphthalene C6–H and C7–H), 7.90 (d, 2H, J_o = 8.69 Hz, benzene H), 8.30 (d, 1H, J_o = 8.47 Hz, naphthalene C3–H), 8.46–8.52 (m, 2H, naphthalene C5–H and C8–H). Anal. ($\text{C}_{18}\text{H}_{16}\text{O}_4\text{S}$) C, H, S.

4-(4-Hydroxymethyl)phenylamino)naphthalen-1-ol (**4h**). A solution of **4j** (350 mg, 1.2 mmol) in anhydrous THF (40 mL) was added dropwise into a 0°C suspension of LiAlH_4 (230 mg, 6.0 mmol) in the same solvent (40 mL). After the addition, the mixture was stirred at room temperature for 15 h. The excess of LiAlH_4 was carefully destroyed with crushed ice, and the precipitate that formed was filtered on a Buchner apparatus. The solution was concentrated, extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine (3×100 mL) and dried over anhydrous Na_2SO_4 . The solvent was evaporated under vacuum, obtaining 320 mg of crude product. Because it was unstable, it was immediately solubilized in 10 mL of methanol and added dropwise to a solution of HCl in methanol cooled at 0°C , prepared by adding dropwise acetyl chloride (2.2 mmol) in methanol (10 mL). The mixture was stirred at 0°C for 5 min after which anhydrous diethyl ether (100 mL) was added and the resulting precipitate was filtered to obtain 220 mg (33%) of hydrochloride **4h**, with mp $> 300^{\circ}\text{C}$.

Biological Assays. In Vitro Assays. Compounds **4a–t**, **5a–c**, **6a–g**, **7a,b**, **8a,b**, and **9a,b** (Table 1) were tested for their ability to inhibit aggregation of $\text{A}\beta_{(1-42)}$, via the binding of the ThT.

Preparation of the Nonaggregate $\text{A}\beta_{(1-42)}$. The $\text{A}\beta_{(1-42)}$ was dissolved in a mixture of acetonitrile and distilled water ($\text{CH}_3\text{CN}/\text{H}_2\text{O}$ 1:1) to a final concentration of 1 mg/mL. The solution was divided in aliquots of 2 mL and stored at -80°C until use. The working solution was prepared, diluting the stock solution with H_2O to get a final concentration of 44 μM .

Preparation of the Aggregate $\text{A}\beta_{(1-42)}$. The $\text{A}\beta_{(1-42)}$ was dissolved in a mixture of acetonitrile and distilled water ($\text{CH}_3\text{CN}/\text{H}_2\text{O}$ 1:1) to the final concentration of 1 mg/mL. An aliquot of 2 mL was freeze-dried to eliminate the trifluoroacetic acid resulting from the peptide synthesis. The $\text{A}\beta_{(1-42)}$ peptide was subsequently dissolved in 0.1 mL of DMSO and 5.0 mL of $2\times$ PBS, pH 7.4. Once dissolved, the $\text{A}\beta_{(1-42)}$ was incubated at 37°C for 8 days. After sonication, it was diluted with $2\times$ PBS to get a final concentration 17.4 μM . The aggregate $\text{A}\beta_{(1-42)}$ was divided in 20 aliquots and stored at -80°C .

Screening of Inhibitory Activity of $\text{A}\beta$ Aggregation (ThT). The drugs to be tested as fibrillogenesis inhibitor were dissolved in a minimum amount of DMSO and then diluted with water to the final concentrations of 10 or 100 μM , with a total percentage of DMSO

inferior to 10%. The assays were performed in triplicate in 96-well plates. The compounds to be tested were added in wells containing the aggregate $\text{A}\beta_{(1-42)}$. Then after 15 min, the nonaggregate $\text{A}\beta_{(1-42)}$ was added. The 96-well plates were incubated at 37°C under agitation for 24 h. The following day 200 μL of a solution containing 10 μM ThT and 50 μM Na_2HPO_4 , pH 6.5, was added to each well. Fluorescence was measured in a VICTOR 2 (WALLAC) fluorescence spectrophotometer (λ_{ex} = 450 nm, λ_{em} = 486 nm).³³

The data are expressed as percent of residual aggregated $\text{A}\beta$, and the dose reducing the aggregate formation of the 50% (IC_{50}) was estimated. The % of aggregation was determined by the following formula:

$$\frac{[(\text{A}\beta + \text{test compound}) - (\text{blank} + \text{test compound})]}{\times 100 / [(\text{control} + \text{A}\beta) - \text{blank}]}$$

Blood–Brain Barrier Crossing. Ten mice were given subcutaneously compound **4q** dissolved in 10% ethanol, 40% PEG-400, and 50% saline and were killed by decapitation under deep anesthesia in order to obtain information on the concentration achieved in brain and its relationship with plasma concentrations. Mixed arteriovenous trunk blood was collected at 0, 15, 30, 60, 120, 180, and 240 min after dosing and centrifuged at 3000g for 10 min, and the plasma was stored at -20°C . Brain was removed immediately, blotted with paper to remove excess surface blood, and quickly frozen in dry ice.

Compound **4q** was extracted from plasma, and brain homogenate was obtained by a solid–liquid extraction procedure and quantified by reverse phase HPLC with UV detection (224 nm). To 0.3 mL of plasma were added 0.3 mL of $\text{CH}_3\text{CN}/0.01$ N phosphate buffer, pH 7.4 (70:30, v/v), and 0.1 mL of a solution of the internal standard. After centrifugation, the supernatants were added to Oasis HLB 1 cc cartridges which were pretreated with methanol and distilled water. Cartridges were washed with methanol–water (15:85 v/v) and then methanol only, interrupting the vacuum before completely drying the column. The compound was removed by eluting the cartridges with methanol (2.5 mL), and the collected fractions evaporated to dryness under nitrogen. The residue was dissolved in the mobile phase, centrifuged, and analyzed by HPLC. Brain tissue was homogenized (1 g/5 mL) in $\text{CH}_3\text{CN}/0.001$ M phosphate buffer, pH 7.4 (70:30, v/v), and a volume containing approximately 100 mg of tissue was centrifuged and processed as for plasma. Separation was done on a $\mu\text{Bondapak}$ C18 column protected by a LiChrosphere RP8 precolumn at room temperature. The mobile phase was $\text{H}_2\text{O}/\text{CH}_3\text{CN}/\text{CH}_3\text{OH}/n\text{-butanol}$ (43:42:14:1, v/v), containing 65 mM ammonium acetate. The retention times were 10.5 min for **4q** and 20.5 for the internal standard.

Mean brain and plasma area under the concentration–time curve over the dosing interval (AUC_t) were determined using the linear trapezoidal rule. The maximum concentration (C_{max}) and the time (t_{max}) were read directly from the plasma and brain concentration time data.

■ ASSOCIATED CONTENT

● Supporting Information

Results from elemental analyses of compounds **2**, **4a–g,i–s**, **5a–c**, **6a–g**, **7b**, **8a,b**, and **9a,b**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*For R.D.S.: phone, +39-06-49913150; fax, +39-06-49913133; e-mail, roberto.disanto@uniroma1.it. For P.M.: phone, +39-06-91393906; fax, +39-06-91393638; e-mail, Patrizia.Minetti@sigma-tau.it.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank Dr. Gilles Pain for his help in reviewing the manuscript.

■ ABBREVIATIONS USED

CR, Congo Red; IL, interleukin; ABBB, alizarin blue-black B; ThT, thioflavin T; BINAP, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl; Pd₂dba₃, tris(dibenzylideneacetone)dipalladium; DPEphos, bis(2-diphenylphosphinophenyl) ether

■ REFERENCES

- (1) World Alzheimer Report 2010; Alzheimer's Disease International: London, 2010.
- (2) Chen, M. The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part II: therapeutic rationale. *Front. Biosci.* **1998**, *3*, a32–a37.
- (3) Billings, L. M.; Oddo, S.; Green, K. N.; McGaugh, J. L.; LaFerla, F. M. Intraneuronal A β causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. *Neuron* **2005**, *45*, 675–688.
- (4) Okamura, N.; Suemoto, T.; Furumoto, S.; Suzuki, M.; Shimadzu, H.; Akatsu, H. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. *J. Neurosci.* **2005**, *25*, 10857–10862.
- (5) Sair, H. I.; Doraiswamy, P. M.; Petrella, J. R. In vivo amyloid imaging in Alzheimer's disease. *Neuroradiology* **2004**, *46*, 93–104.
- (6) Mathis, C. A.; Klunk, W. E.; Price, J. C.; DeKosky, S. T. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. *Arch. Neurol.* **2005**, *62*, 196–200.
- (7) Villemagne, V. L.; Rowe, C. C.; Macfarlane, S.; Novakovic, K. E.; Masters, C. L. Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. *J. Clin. Neurosci.* **2005**, *12*, 221–230.
- (8) Lorenzo, A.; Yankner, B. A. 8-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 12243–12247.
- (9) Frandrich, M. On the structural definition of amyloid fibrils and other polypeptides aggregates. *Cell. Mol. Life Sci.* **2007**, *64*, 2066–2078.
- (10) Iverfeldt, K.; Walaas, S. I.; Greengard, P. Altered processing of Alzheimer amyloid precursor protein in response to neuronal degeneration. *Proc. Natl. Acad. Sci. U.S.A.* **1993**, *90*, 4146–4150.
- (11) Masters, C. L.; Cappai, R.; Barnham, K. J.; Villemagne, V. L. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. *J. Neurochem.* **2006**, *97*, 1700–1725.
- (12) Galimberti, D.; Scarpini, E. Alzheimer's disease: from pathogenesis to disease-modifying approaches. *CNS Neurol. Disord.: Drug Targets* **2011**, *10*, 163–174.
- (13) Glabe, C. C. Amyloid accumulation and pathogenesis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar A β . *Subcell. Biochem.* **2005**, *38*, 167–177.
- (14) Re, F.; Airoldi, C.; Zona, C.; Masserini, M.; La Ferla, B.; Quattrocchi, N.; Nicotra, F. Beta amyloid aggregation inhibitors: small molecules and candidate drugs for therapy of Alzheimer's disease. *Curr. Med. Chem.* **2010**, *17*, 2990–3006.
- (15) Sabbagh, M. N.; Galasko, D.; Thal, L. J. Amyloid-beta and treatment opportunities for Alzheimer's disease. *J. Alzheimer's Dis.* **2000**, *2*, 231–259.
- (16) Rogers, J. Y.; Lahiri, D. K. Metal and inflammatory target for Alzheimer's disease. *Curr. Drug Targets* **2004**, *5*, 535–551.
- (17) Dodel, R. C.; Hampel, H.; Du, Y. Immunotherapy for Alzheimer's disease. *Lancet Neurol.* **2003**, *2*, 215–220.
- (18) Levine, H., III. Small molecules inhibitors of A β assembly. *Amyloid* **2007**, *14*, 185–197.
- (19) Gisponer, J.; Haberthur, U.; Caflich, A. The role of side-chain interactions in the early steps of aggregation: molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100*, 5154–5159.
- (20) Hills, R. D., Jr.; Brooks, C. L., III. Hydrophobic cooperativity as a mechanism for amyloid nucleation. *J. Mol. Biol.* **2007**, *368*, 894–901.
- (21) Covertino, M.; Pellarin, R.; Catto, M.; Carotti, A.; Caffish, A. 9,10-Antraquinone hinders beta-aggregation: How does a small molecule interfere with A β -peptide amyloid fibrillation? *Protein Sci.* **2009**, *18*, 792–800.
- (22) Zheng, J.; Ma, B.; Nussinov, R. Consensus features in amyloid fibrils: sheet-sheet recognition via a (polar or nonpolar) zipper structure. *Phys. Biol.* **2006**, *3*, 1–4.
- (23) Keowkase, R.; Luo, Y. Mechanism of CNS drugs and their combinations for Alzheimer's disease. *Cent. Nerv. Syst. Agents Med. Chem.* **2008**, *8*, 241–248.
- (24) Le Vine, H., III. Stopped-flow kinetics reveal multiple phases of thioflavin T binding to Alzheimer β (1–40) amyloid fibrille. *Arch. Biochem. Biophys.* **1997**, *342*, 306–316.
- (25) Le Vine, H., III. Thioflavin T. interaction with synthetic Alzheimer's disease β -amyloid peptide: detection of amyloid aggregation in solution. *Protein Sci.* **1993**, *2*, 404–410.
- (26) Kimler, B. F.; Rethorst, R. D.; Cox, G. G. Investigation of the interaction of cardiotoxic anticancer agents using the fetal mouse heart organ culture system. *Invest. New Drugs* **1986**, *4*, 127–133.
- (27) Simons, L. J.; Caprathe, B. W.; Callahan, M.; Graham, J. M.; Rimura, T.; Lai, Y.; LeVine, H., III; Lipinski, W.; Sakkab, A. T.; Tasaki, Y.; Walzer, L. C.; Yasunaga, T.; Ye, Y.; Zhuang, N.; Augelli-Szafran, C. E. The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 654–657.
- (28) Arumugan, K.; Subramanian, G. S.; Mallayasamy, S. R.; Averinemi, R. K.; Reddy, M. S.; Udupa, N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. *Acta Pharm.* **2008**, *58*, 287–297.
- (29) Matsui, K.; Mishima, M.; Nagai, Y.; Yuzuriha, T.; Yoshimura, T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to rat. *Drug Metab. Dispos.* **1999**, *27*, 1406–1414.
- (30) McNally, W. P.; Pool, W. F.; Sinz, M. W.; Dehart, P.; Ortwine, D. F.; Huang, C. C.; Chang, T.; Woolf, T. F. Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue. *Drug Metab. Dispos.* **1996**, *24*, 628–633.
- (31) Bounce, N. J.; Cater, S. R.; Scaiano, J. C.; Johnston, L. J. Photosubstitution of 1-methoxy-4-nitronaphthalene with amine nucleophiles: dual pathways. *J. Org. Chem.* **1987**, *52*, 4214–4223.
- (32) Glennon, R. A.; Naiman, N. A.; Pierson, M. E.; Smith, J. D.; Ismaiel, A. M.; Titeler, M.; Lyon, R. A. N-(Phthalimidoalkyl) derivatives of serotonergic agents: a common interaction at 5-HT_{1A} serotonin binding sites. *J. Med. Chem.* **1989**, *32*, 1921–1926.
- (33) Minetti, P.; Di Santo, R. Naphthyl Derivatives Inhibitors of beta-Amyloid Aggregation. International Patent Application WO2007045593, 2007.
- (34) Suzuki, H.; Nonoyama, N. Nitrogen dioxide-sodium iodide as an efficient reagent for the one pot conversion of aryl iodides under non aqueous conditions. *Tetrahedron Lett.* **1998**, *39*, 4533–4536.